CardiovasculaR and haematological sUrvivorship iN breast Cancer patients at High risk caused bY Clonal Hematopoiesis of Indeterminate Potential - Study
- Conditions
- clonal hematopoiesis of indeterminate potential
- Registration Number
- DRKS00031021
- Lead Sponsor
- niversitätsklinik Essen
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Female
- Target Recruitment
- 100
Inclusion Criteria
First diagnosis of non-metastasized breast cancer
Exclusion Criteria
Male gender
Metastasized breast cancer
Former history of acute myeloid leukemia, myeloproliferative diseases, or myelodysplastic syndrome
Prior therapies with cytotoxic agents (excluding methotrexate for autoimmune diseases)
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To estimate the willingness of participation with an accuracy of +/- 7.5%.
- Secondary Outcome Measures
Name Time Method - to assess the patient acceptance of the study procedures and addition of CHIP diagnostics to the routine work-up<br>- to evaluate the overall prevalence of pre-therapeutic CHIP in this cohort of breast cancer patients<br>- to characterize the prevalence of cardiovascular risk factors in CHIP-positive versus CHIP-negative patients